AI-Powered wristband aims to quiet essential tremor without drugs

NCT ID NCT06235190

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests a wrist-worn device called Felix that uses artificial intelligence to deliver gentle nerve stimulation, aiming to reduce hand tremors in people with essential tremor. Participants wear the device daily for up to 90 days and are compared to a group using a sham (inactive) device. The goal is to see if the device safely improves tremor-related daily activities and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Felix NeuroAI Wristband (transcutaneous neurostimulation device)
What this could lead to
If it works, this could offer a noninvasive, drug-free option for managing essential tremor throughout the day.
What could go wrong
This is an early-stage study with a sham comparison, so results may not confirm lasting benefit. The device may not work for everyone, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

125 people

The number who actually took part.

Started

Feb 2024

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years of age. * Willing to provide written, informed consent to participate in the study. * A clinical diagnosis of ET by a movement disorder specialist. * For the dominant hand, a tremor severity score of 2 or higher as measured by one of the TETRAS Performance Subscale (PS) tasks (items 4, 6, 7, and 8) and a total score of 7 or higher across these items. If applicable, this must be met while the patient is on ET treatment. * Stable dosage of anti-tremor medications, if applicable, for 30 days prior to study entry. * Stable dosage of antidepressant medications, if applicable, for 90 days prior to study entry. * Familiar with operating a touch-screen smartphone and connecting to Wi-Fi internet at home. * If necessary, have a dedicated caregiver to help with study required activities, such as putting on the study device, etc. * Willing to comply with study protocol requirements including: 1. Remaining on a stable dosage of anti-tremor and antidepressant medications, if applicable, during the course of the study. 2. Do not start any new anti-tremor treatment during the course of the study (except the assigned treatment in the study). 3. Remaining on stable caffeine consumption, if applicable, during the course of the study. 4. No alcohol or marijuana consumption the day before a study visit. 5. Do not share study/device-related information on the internet or with other study patients. Exclusion Criteria: * Prior limb amputation or any known symptomatic peripheral neuropathy condition of the involved upper extremity. * Prior surgical intervention for ET such as deep brain stimulation or thalamotomy. * Moderate to severe alcohol use disorder (AUD) as per Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) (the presence of at least 4 symptoms or more). * Any current drug abuse. * Use of recreational drugs other than marijuana. * Current unstable epileptic conditions with a seizure within 6 months of study entry. * Other possible causes of tremor such as drug-induced tremor, enhanced physiological tremor, dystonia, and Parkinson's disease. * Pregnant or nursing subjects and those who plan pregnancy during the course of the study. * Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at the stimulation site. * Known allergy to adhesive bandages. * The presence of any cognitive or other impairment that in the judgement of the investigator will impede the assessment of study outcomes. * Botulinum Toxin injection for hand tremor within 4 months prior to study enrollment. * History of use of other transcutaneous afferent patterned stimulation (TAPS) devices such as Cala Trio. * Subject is currently participating or has participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor. * Subject is unable to communicate with the investigator and study staff. * Any health condition that in the investigator's opinion should preclude participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential tremor are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Barrow Neurological Institute

    Phoenix, Arizona, 85013, United States

  • Columbia University Irving Medical Center

    New York, New York, 10032, United States

  • Houston Methodist Research Institute

    Houston, Texas, 77030, United States

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida, 33486, United States

  • Parkinson's Research Centers of America - Long Island

    Commack, New York, 11725, United States

  • Parkinson's Research Centers of America - Palo Alto

    Palo Alto, California, 94301, United States

  • Sir Run Run Shaw Hospital

    Hangzhou, Zhejiang, 310016, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310003, China

  • The University Of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

  • Tianjin Medical University General Hospital

    Tianjin, 300052, China

  • University of Cincinnati

    Cincinnati, Ohio, 45221, United States

  • Xuanwu Hospital Capital Medical University

    Beijing, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.